SEMAGLUTIDE IS MORE EFFECTIVE FOR WEIGHT LOSS IN WOMEN COMPARED TO MEN, BUT BOTH BENEFIT IF DIAGNOSED WITH HEART FAILURE.

-

SEMAGLUTIDE IS MORE EFFECTIVE FOR WEIGHT LOSS IN WOMEN COMPARED TO MEN, BUT BOTH BENEFIT IF DIAGNOSED WITH HEART FAILURE.


    


Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves symptoms in men and women with a common type of heart failure that has had few therapeutic options. Women experienced more significant weight loss and the same symptom benefits compared with men, according to research presented today by Dr. Subodh Verma (St. Michael's Hospital, University of Toronto) at the American Diabetes Association's 2024 Scientific Sessions and published in the Journal of the American College of Cardiology (JACC).

This secondary analysis of the STEP-HFpEF (Semaglutide Treatment Effect in People with Obesity and HFpEF) program reveals that semaglutide provides benefits for men and women that do not track directly with weight loss, suggesting the drug may also have weight-loss-independent effects on the cardiovascular system. The study (which included two trials) compared semaglutide with a placebo over 52 weeks in 1,145 participants, highlighting intriguing sex differences.

The analysis sought to determine whether phenotypic features and treatment effects of semaglutide vary by sex in obesity-related heart failure (HF) with preserved ejection fraction (HFpEF). It evaluated the influence of sex on the disease's baseline characteristics. It compared the effects of semaglutide versus placebo on critical trial endpoints in the STEP-HFpEF program (comprised of STEP-HFpEF and STEP-HFpEF DM Trials).

"Understanding the sex differences in obesity-related HFpEF is of great importance. Obesity and visceral adiposity are key drivers of HFpEF development and progression, and this may be even more amplified in women, who represent the majority of people with the disease, and bear a heavier burden of symptoms and physical limitations due to HFpEF" said Mikhail Kosiborod, MD, FACC, senior author of the study and a cardiologist at Saint Luke's Mid-America Heart Institute in Kansas City, Missouri. "Our study sheds light on these differences and the consistent benefits of semaglutide for women and men."

Lead author Dr. Subodh Verma commented that "women living with obesity and heart failure with a preserved ejection fraction were also found to have higher BMI's compared to men, and were much more symptomatic at baseline."

"Females had more systemic inflammation and compared to previous HfpEF studies, females with obesity-related HfpEF were also younger," Verma said.

The study analyzed the effects of semaglutide 2.4 mg administered to participants once weekly vs placebo on the STEP-HFpEF program's dual primary and confirmatory secondary and exploratory outcomes by sex. A total of 1,145 participants with obesity-related HFpEF were evaluated over 52 weeks, of which 570 were females.

Semaglutide, compared with placebo, similarly improved HF-related symptoms, physical limitations, exercise function, and reduced inflammation and natriuretic peptides regardless of sex.

Semaglutide-mediated improvements in HF-related symptoms and physical limitations were consistent in male and female participants across key subgroups, including age and BMI. It also lowered their systolic blood pressure and waist circumference.

However, there were sex differences in the treatment effects in terms of the reduction in body weight with semaglutide. Female participants experienced more significant weight loss than males, with a mean difference of -9.6% vs -7.2%. Even though there was a substantial reduction in body weight in both sexes, it was greater in females (a statistically significant interaction).

At baseline, females with higher left ventricular ejection fraction presented with worse symptoms and physical limitations. They had higher levels of inflammation at baseline but similar rates of hypertension and diuretic use and less atrial fibrillation compared with males despite their higher BMI. Researchers note that this may indicate that more female participants had a typical obesity phenotype of HFpEF compared with males, who may also have left atrial myopathy HFpEF complicated by an increase in BMI.

In an accompanying editorial, Anuradha Lala, MD, a cardiologist at the Mount Sinai School of Medicine and Director of Heart Failure Research for the NHLBI Cardiothoracic Surgery Network, said there is a need for further studies to illuminate the mechanism by which this drug provides benefits and continued attention to sex-specific differences in treatment responses.



Comments

Post a Comment

Popular posts from this blog

PEOPLE WITH OBESITY BURN LESS CALORIES DURING THE DAY

-
Image
  PEOPLE WITH OBESITY BURN LESS CALORIES DURING THE DAY Building on prior studies with healthy-weight participants, the new research includes different body sizes.         New research indicates that weight influences how and when bodies burn energy. An Oregon Health & Science University study published in the journal  Obesity  found people who have a healthy weight use more energy during the day, when most people are active and eat, while those who are obese spend more energy during the night when most people sleep. The study also found that during the day, those with obesity have higher levels of the hormone insulin -- a sign that the body is working harder to use glucose, an energy-packed sugar. "It was surprising to learn how dramatically the timing of when our bodies burn energy differed in those with obesity," said the study's first author, Andrew McHill, Ph.D., an assistant professor at the OHSU School of Nursing and the Oregon Institute of ...
Read more

WHAT CAUSES ITCHING, AND WHAT STOPS IT?

-
Image
  WHAT CAUSES ITCHING, AND WHAT STOPS IT?         It can be a relief to scratch the occasional itch, but when itch gets out of control, it can become a severe health problem. How does the body know when to stop? Scientists at UC San Francisco are getting close to an answer. In a breakthrough that could transform how doctors treat conditions from eczema to allergies, they have discovered a feedback loop centered on a single immune protein called IL-31 that causes the urge to itch and dials back nearby inflammation. The findings, published on October 13th in  Science Immunology , lay the groundwork for a new generation of drugs that interact more intelligently with the body's innate self-regulating ability. Previous approaches suggested that IL-31 signals itch and promotes skin inflammation. However, the UCSF team discovered that nerve cells, or neurons, that respond to IL-31, triggering a scratch, also prevent immune cells from overreacting and causing more ...
Read more

A VEGAN DIET IMPROVES CARDIOVASCULAR HEALTH, ACCORDING TO A NEW STUDY

-
Image
  A VEGAN DIET IMPROVES CARDIOVASCULAR HEALTH, ACCORDING TO A NEW STUDY         In a study with 22 pairs of identical twins, Stanford Medicine researchers and their colleagues have found that a vegan diet improves cardiovascular health in as little as eight weeks. Although it's well-known that eating less meat improves cardiovascular health, diet studies often need to be enhanced by genetic differences, upbringing, and lifestyle choices. By studying identical twins, however, the researchers were able to control for genetics and limit the other factors, as the twins grew up in the same households and reported similar lifestyles. "Not only did this study provide a groundbreaking way to assert that a vegan diet is healthier than the conventional omnivore diet, but the twins were also a riot to work with," said Christopher Gardner, Ph.D., the Rehnborg Farquhar Professor and a professor of medicine. "They dressed the same, they talked the same, and they had a banter ...
Read more